Log In
BCIQ
Print this Print this
 

BL-8020

  Manage Alerts
Collapse Summary General Information
Company Genoscience Pharma
DescriptionFixed-dose combination of ribavirin and hydroxychloroquine that inhibits HCV-induced autophagy in host cells
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase I/II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation
PartnerBioLineRx Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/30/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today